

CLAIMS

1. A composition comprising an immunoglobulin comprising the mutations Q311R, N434W and M428E, wherein said immunoglobulin has altered binding to FcRn, and wherein said immunoglobulin is
IgG1-Q311R/N434W/M428E.
2. The composition of claim 1, wherein said mutation extends the serum half-life of the immunoglobulin as compared to an immunoglobulin lacking said mutation.
3. The composition of claim 1 or 2, wherein the constant region of said immunoglobulin comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 and 7.
4. The composition of any one of claims 1 to 3, wherein said immunoglobulin binds to a target selected from the group consisting of a cancer marker, a cytokine, an infectious disease marker, and a growth factor.
5. An Fc fusion comprising an Fc variant from the immunoglobulin as defined in any one of claims 1 to 4.
6. A fusion protein comprising the immunoglobulin as defined in any one of claims 1 to 4 or the Fc region the immunoglobulin as defined in any one of claims 1 to 4 fused to an immunogen.
7. A vaccine composition comprising the fusion protein of claim 6.
8. The vaccine composition of claim 7 for use in the generation of an immune response in a subject.
9. Use of the vaccine composition of claim 7 in the manufacture of a medicament for the generation of an immune response to said immunogen in a subject.